ArticleFrontiers in medicine2026
Bushen Huoxue recipe restores trophoblast proliferation through the PI3K/AKT pathway in recurrent spontaneous abortion.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysregulation of extravillous trophoblast (EVT) proliferation and invasion has been implicated in the pathogenesis of recurrent spontaneous abortion (RSA). Bushen Huoxue Recipe (BSHXR), a Traditional Chinese Medicine formula for RSA, has notable clinical efficacy; however, the molecular mechanisms by which it ameliorates recurrent spontaneous abortion remain to be elucidated. Objective: This study aimed to identify the key active ingredients in BSHXR and observe the mechanism by which BSHXR alleviates RSA. Methods: BSHXR compounds were identified by UPLC-Q-TOF-MS/MS. Transcriptome sequencing and network pharmacology were performed to identify potential key genes and pathways involved in the therapeutic effects of BSHXR. A miscarriage model was established in mice, and the embryo loss rate, ELISA, and HE staining were used to explore the effect of BSHXR. In combination with bioinformatics analyses, we used immunoblotting and immunofluorescence to elucidate the regulatory mechanisms of BSHXR Results: Transcriptome analysis suggests that the pathogenesis of RSA may be associated with cell proliferation and the PI3K/AKT pathway. A total of 155 chemical constituents of BSHXR were identified, along with 267 therapeutic targets, for treating RSA, and the main chemical components of BSHXR stably interact with key genes of the PI3K/AKT pathway. In the BSHXR group, the rate of embryonic loss was significantly reduced ( Conclusion: The PI3K/AKT pathway is a potential pathway for RSA intervention. The therapeutic effect of BSHXR is related to the proliferative effect mediated by the PI3K/AKT pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.